Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

This study tests whether adding tislelizumab (an immunotherapy drug) to standard chemotherapy before definitive chemoradiation improves outcomes for patients with locally advanced esophageal squamous cell carcinoma (ESCC) that cannot be surgically removed. This approach — induction therapy followed by definitive concurrent chemoradiotherapy — aims to shrink the tumor first, then eliminate it with combined treatment. **You may be eligible if...** - You are between 18 and 70 years old - You have confirmed ESCC at stage II–IVA that is inoperable (either medically unfit for surgery or choosing non-surgical treatment) - You have not received prior treatment for esophageal cancer - Your ECOG performance score is 0 or 1 (able to care for yourself) - Your blood counts and organ function meet the study requirements **You may NOT be eligible if...** - Your cancer has spread to distant organs - You have had prior treatment for esophageal cancer - You have an active autoimmune disease - You are taking long-term steroids or immune-suppressing medications - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.